Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Scott Health Services LLC

Neither a doctor nor a teaching hospital

Research payments

$2,338,192

298 payments

Through program year 2025, Scott Health Services LLC is reported as receiving $2,338,192 in research payments, across 298 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $9,679 3
2024 Research $175,528 22
2023 Research $346,574 40
2022 Research $194,870 37
2021 Research $371,059 83
2020 Research $455,509 75
2019 Research $784,973 38

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $1,153,301 71 payments
  2. Acrotech Biopharma LLC $397,331 29 payments
  3. AbbVie, Inc. $175,544 52 payments
  4. Pfizer Inc. $164,308 46 payments
  5. Janssen Research & Development, LLC $112,040 24 payments
  6. LEO Pharma AS $104,916 21 payments
  7. VYNE Pharmaceuticals Inc. $63,353 8 payments
  8. Genentech, Inc. $43,467 16 payments
  9. Amgen Inc. $31,816 11 payments
  10. Celgene Corporation $27,980 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-To-Severe Plaque Psoriasis $342,072 5 payments
  2. 246-13651-302 $211,020 15 payments
  3. A Multicenter, Long-Term Extension to Evaluate the Long-Term Safety and Maintenance of Treatment Effect of Ly3074828 in Patients With Moderate-To-Severe Plaque Psoriasis Oasis-3 $166,658 4 payments
  4. 246-13651-301 $155,202 12 payments
  5. A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Ly3471851 in Patients With Psoriasis $148,413 3 payments
  6. Assessment of Safety, Tolerability, and Efficacy of Ly3303560 in Early Symptomatic Alzheimer's Disease $141,046 3 payments
  7. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Or Very Severe Alopecia Areata $126,625 8 payments
  8. A Phase 2A Multicenter Randomized Doubleblind Placebocontrolled 16Week Study Evaluating the Safety and Efficacy of Pf06650833 Pf06700841 and Pf06826647 in Adults With Moderate to Severe Hidradenitis Suppurativa $106,288 30 payments
  9. A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis $71,317 4 payments
  10. Long-Term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - Ecztend $67,676 16 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record